help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First Published Online August 14, 2009
The Oncologist, Vol. 14, No. 8, 780-793, August 2009; doi:10.1634/theoncologist.2009-0019
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2009-0019v1
14/8/780    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Google Scholar
Right arrow Articles by Boss, D. S.
Right arrow Articles by Schellens, J. H.M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boss, D. S.
Right arrow Articles by Schellens, J. H.M.

Clinical Pharmacology

Clinical Experience with Aurora Kinase Inhibitors: A Review

David S. Bossa, Jos H. Beijnenac, Jan H.M. Schellensa,b

aDivision of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; bUtrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht, The Netherlands; cDepartment of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands

Key Words. Aurora kinase • Mitosis • Targeted therapy • Drug development • Clinical trial

Correspondence: Jan H.M. Schellens, M.D., Ph.D., The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Telephone: 31-20-512-2569; Fax: 31-20-512-2572; e-mail: jhm{at}nki.nl

Received February 1, 2009; accepted for publication July 6, 2009; first published online in THE ONCOLOGIST Express on August 14, 2009.

Disclosures: David S. Boss: None; Jos H. Beijnen: None; Jan H.M. Schellens: Consultant/advisory role: AstraZeneca; Research funding/contracted research: AstraZeneca.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

The aurora kinase family of serine/threonine kinases comprises three members, designated auroras A, B, and C. Auroras A and B are essential components of the mitotic pathway, ensuring proper chromosome assembly, formation of the mitotic spindle, and cytokinesis. The role of aurora C is less clear. Overexpression of aurora A and B has been observed in several tumor types, and has been linked with a poor prognosis of cancer patients. Several small molecules targeting aurora kinases A and B or both have been evaluated preclinically and in early phase I trials. In this review we aim to summarize the most recent advances in the development of aurora kinase inhibitors, with a focus on the clinical data.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.